Skip to main content

2016 First Annual Oncology Guide to New FDA Approvals

FDA Updates

Imlygic (Talimogene Laherparepvec): First Oncolytic Viral Therapy for the Treatment of Patients with Recurrent Melanoma

Lisa A. Raedler, PhD, RPh, Medical Writer

FDA Updates

Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström’s Macroglobulinemia

Lisa A. Raedler, PhD, RPh, Medical Writer

FDA Updates

Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma

Lisa A. Raedler, PhD, RPh, Medical Writer

FDA Updates, Monoclonal Antibodies

Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma

Lisa A. Raedler, PhD, RPh, Medical Writer

FDA Updates

Bendeka (Bendamustine Hydrochloride): Rapid-Infusion Formulation Approved for Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphomas

Lisa A. Raedler, PhD, RPh, Medical Writer

FDA Updates, Tyrosine Kinase Inhibitor

Alecensa (Alectinib), an Oral Tyrosine Kinase Inhibitor, Approved for Metastatic Non–Small-Cell Lung Cancer with ALK Mutation

FDA Updates

FDA Approvals of Brand-Name Prescription Drugs in 2015

FDA Updates

Translation of Benchtop Science Arrives in Force, Improves Patient Care

Val R. Adams, PharmD, BCOP, FCCP, FHOPA

1
2

Page 2 of 2
Results 11 - 18 of 18